Securities code: Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) securities abbreviation: Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Announcement No.: 2022014 Wanbangde Pharmaceutical Holding Group Co.Ltd(002082)
Announcement on the resolutions of the 14th meeting of the 8th board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) (hereinafter referred to as “the company”) the notice of the 14th meeting of the 8th board of supervisors was sent by telephone and wechat on April 2, 2022, and the meeting was held by means of communication voting on April 13, 2022. Three supervisors should be present at this meeting and three actually present. The convening, convening and voting procedures of the meeting shall comply with relevant laws, administrative regulations, departmental rules, normative documents, the articles of association and other relevant provisions.
2、 Deliberation at the meeting of the board of supervisors
The meeting deliberated and adopted the following proposals by open ballot:
1. Deliberated and adopted the work report of the board of supervisors in 2021
Voting results: 3 in favor, 0 against and 0 abstention.
Details are disclosed on cninfo.com.cn on the same day Work report of the board of supervisors in 2021.
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
2. Deliberated and adopted the financial statement report for 2021
Voting results: 3 in favor, 0 against and 0 abstention.
Details are disclosed on cninfo.com.cn on the same day Financial final accounts report of 2021.
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
3. Reviewed and approved the profit distribution plan for 2021
Voting results: 3 in favor, 0 against and 0 abstention.
According to the articles of association, dividend management system and other relevant provisions, the company has major investment plans or major cash expenditures in new product R & D, API production base and international preparation workshop in the next 12 months. In 2021, the company plans not to carry out cash dividends or the distribution plan of converting capital reserve into share capital. The plan is formulated according to the actual situation of the company and complies with the relevant provisions of relevant laws, regulations and the articles of association.
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation.
4. Deliberated and passed the proposal on the provision for asset impairment;
Voting results: 3 in favor, 0 against and 0 abstention.
The company’s provision for asset impairment this time complies with the relevant provisions of the accounting standards for business enterprises and the company’s relevant accounting systems, the actual situation of the company’s assets and operation, and the review procedures are legal, compliant and based on sufficient basis. After the provision for asset impairment is withdrawn this time, it can more fairly reflect the asset status and operating results of the company. Agree to the provision for asset impairment this time.
Details are disclosed in the securities times, Securities Daily, Shanghai Securities News, China Securities News and cninfo (www.cn. Info. Com. CN) on the same day Announcement on the provision for impairment of goodwill (Announcement No.: 2022016).
5. The annual report for 2021 and its summary were considered and adopted
Voting results: 3 in favor, 0 against and 0 abstention.
The 2021 annual report and its summary prepared and reviewed by the board of directors of the company comply with laws, administrative regulations and the provisions of the CSRC. The full text and abstract of the company’s 2021 annual report truly, accurately and completely reflect the actual situation of the company, and there are no false records, misleading statements or major omissions. Details are disclosed in the securities times, Securities Daily, Shanghai Securities News, China Securities News and cninfo (www.cn. Info. Com. CN) on the same day Abstract of the company’s 2021 annual report (Announcement No.: 2022015); The 2021 annual report of the company was disclosed on cninfo.com.cn on the same day.
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
6. The proposal on self-evaluation report on internal control in 2021 was considered and adopted
Voting results: 3 in favor, 0 against and 0 abstention.
The company’s existing internal control system meets the requirements of national laws and regulations, meets the actual needs of the current company’s operation, has been effectively implemented in the company’s operation and management, and has played a good role in control and prevention. The self-evaluation report on internal control in 2021 issued by the board of directors objectively and truly reflects the current situation of the company’s internal control.
Details are disclosed on cninfo.com.cn on the same day Self evaluation report on internal control of the company in 2021.
7. Deliberated and passed the proposal on the company’s 2022 annual guarantee plan;
Voting results: 3 in favor, 0 against and 0 abstention.
Details are disclosed in the securities times, Securities Daily, Shanghai Securities News, China Securities News and cninfo (www.cn. Info. Com. CN) on the same day Announcement on the company’s 2022 annual guarantee plan (Announcement No.: 2022017).
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
8. Deliberated and adopted the proposal on providing financial assistance to holding subsidiaries and their subsidiaries;
Voting results: 3 in favor, 0 against and 0 abstention.
Details are disclosed in the securities times, Securities Daily, Shanghai Securities News, China Securities News and cninfo (www.cn. Info. Com. CN) on the same day Announcement on providing financial assistance to holding subsidiaries and their subsidiaries (Announcement No.: 2022018).
This proposal still needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
9. The proposal on renewing the appointment of audit institutions in 2022 was considered and adopted
Voting results: 3 in favor, 0 against and 0 abstention.
After review, the board of supervisors agreed to reappoint Dahua Certified Public Accountants (special general partnership) as the company’s audit institution in 2022.
Details are disclosed in the securities times, Securities Daily, Shanghai Securities News, China Securities News and cninfo (www.cn. Info. Com. CN) on the same day Announcement on reappointment of the company’s audit institution in 2022 (Announcement No.: 2022020).
3、 Documents for future reference
1. Resolutions of the 14th meeting of the 8th board of supervisors.
It is hereby announced.
Wanbangde Pharmaceutical Holding Group Co.Ltd(002082)
Board of supervisors
April 14, 2002
